Citations

Showing 10 of 108135 citations.

A single‐institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting
Hazim, Antonious , Ruan, Gordon , Slusser, Joshua P. , Marshall, Ariela L. , Pruthi, Rajiv K. , Hazim, Antonious Z , Ruan, Gordon J , Pruthi, Rajiv K , Marshall, Ariela , Khodadadi, Ryan B.

Mayo Clinic

International Journal of Laboratory Hematology | October 7, 2021 | Volume: 44 | Issue: 1 | Pages: 209-215

10.1111/ijlh.13727 | PMID 34612006 Get It

AbstractIntroductionAn algorithmic approach, termed the prolonged clot time profile (PROCT), consisting of initial screening with prothrombin time (PT) and activated partial thromboplastin time (aPTT), reflexive mixing studies if indicated, and follow‐up assays depending on initial testing results, offers an efficient approach to delineate the etiology of a prolonged PT/aPTT. Herein, we present the outcomes of the PROCT in the outpatient setting.MethodsIn this retrospective study, we reviewed medical records of consecutive outpatients who had prolonged PT and/or aPTT noted in the routine coagulation laboratory and who had PROCT ordered in our institutional Special Coagulation Laboratory between 2010 and 2017.ResultsOne hundred and six patients, median age 55 years (IQR 30‐67), met our study criteria. Twenty‐nine patients had normal PT/aPTT, while 77 had persistent abnormalities and underwent reflexive testing. A prolonged PT, aPTT, or PT and aPTT was noted in 27 (35%), 27 (35%), and 23 (30%) respectively. Forty‐nine (64%) had an acquired condition, 17 (22%) had a congenital condition, 7 (9%) had unclear etiology, and 4 (5%) were the result of laboratory artifact. The most common known cause of an isolated prolonged PT in our study was vitamin K deficiency in 8 (10%), the most common cause of an isolated prolonged aPTT was lupus anticoagulant in 4 (5%), and the most common cause of prolonged PT and aPTT was liver disease in 11 (14%).ConclusionProlonged PT/aPTT have a wide range of causes, including artifactual prolongation or abnormalities in secondary hemostasis due to both inherited and acquired conditions.
Evaluation and Management of Acute Myelopathy
Sechi, Elia , Flanagan, Eoin P.

Mayo Clinic

Seminars in Neurology | October 7, 2021 | Volume: 41 | Issue: 05 | Pages: 511-529

10.1055/s-0041-1733792 | PMID 34619778 Get It

AbstractAcute myelopathies are spinal cord disorders characterized by a rapidly progressive course reaching nadir within hours to a few weeks that may result in severe disability. The multitude of underlying etiologies, complexities in confirming the diagnosis, and often unforgiving nature of spinal cord damage have always represented a challenge. Moreover, certain slowly progressive myelopathies may present acutely or show abrupt worsening in specific settings and thus further complicate the diagnostic workup. Awareness of the clinical and magnetic resonance imaging characteristics of different myelopathies and the specific settings where they occur is fundamental for a correct diagnosis. Neuroimaging helps distinguish compressive etiologies that may require urgent surgery from intrinsic etiologies that generally require medical treatment. Differentiation between various myelopathies is essential to establish timely and appropriate treatment and avoid harm from unnecessary procedures. This article reviews the contemporary spectrum of acute myelopathy etiologies and provides guidance for diagnosis and management.
The “Changing Landscapes” Special Edition
Lacy, Brian E. , Spiegel, Brennan , Spiegel, Brennan , Lacy, Brian E.

Mayo Clinic

American Journal of Gastroenterology | October 7, 2021 | Volume: 116 | Issue: 10 | Pages: 1969-1969

10.14309/ajg.0000000000001512 | PMID 34618694 Get It

Hinfp is a guardian of the somatic genome by repressing transposable elements
Nirala, Niraj K. , Li, Qi , Ghule, Prachi N. , Chen, Hsi‐Ju, Li, Rui , Zhu, Lihua Julie , Rice, Nicholas , Mao, Junhao , Stein, Janet L. , Wijnen, André J. van , Ip, Y. Tony , Rice, Nicholas P , Stein, Gary S , van Wijnen, Andre J , Ip, Y Tony , Wang, Ruijia , Stein, Gary S.

Mayo Clinic

Proceedings of the National Academy of Sciences | October 7, 2021 | Volume: 118 | Issue: 41 | Pages: No page available

10.1073/pnas.2100839118 | PMID 34620709 Get It

Significance Repression of the large number of transposable elements in eukaryotic genomes is essential for genome stability. The Piwi-interacting RNA and short interfering RNA pathways are critical for repressing transposable elements in germlines, but the repression of transposable elements in somatic tissues involves other components. While the mammalian Hinfp has been shown to regulate Histone4 and cell-cycle progression, our manuscript provides evidence that a function of the Drosophila Hinfp is to maintain Histone1 expression to repress most transposable elements in somatic genomes. This Hinfp–Histone1 axis provides a venue to study maintenance of genome stability and progression of pathological outcomes.
P077 Reliability of the Clinical Characterization of Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A46-A46

10.1093/sleepadvances/zpab014.121 Get It

Abstract Purpose Compare agreements between polysomnography-based (PSG) diagnosis of isolated REM-sleep-behavior-disorder (iRBD) and Non-REM-Hypertonia (NRH), a novel biomarker independently associated with synucleinopathy-related neurodegenerative diseases. Methods Sixteen patients with histories of dream-enactment-behavior (DEB)(women=38%; age:64.6±13.0) underwent PSG with simultaneously-recorded Sleep Profiler (SP). Two boarded sleep neurologists independently characterized iRBD. Physician1 combined abnormal qualitative REM-sleep-without-atonia (RSWA) by submental electromyography, with video-confirmation of probably DEB. Physician2 relied solely on qualitative RSWA. SP was auto-staged, technically reviewed, and reprocessed for automated abnormal NRH detection. Kappa scores measured physician and NRH agreements. Results In the 14 records with REM sleep, iRBD was characterized in: Physician1=64%, Physician2=79%, NRH=71% of the records. Across the three methods, unanimous iRBD agreement occurred in 57% of the records (positive=7, negative=1). The between-physician agreement in iRBD classifications was fair (kappa=0.32). The agreement between NRH and Physician1 was moderate (kappa=0.52) versus slight with Physician2 (kappa=0.05). NRH comparisons to consensus physician agreement yielded one false-positive and one false-negative iRBD finding. Physician2 classified: a) iRBD in two cases that were negative by Physician1 and NRH, and b) one negative case that Physician1 and NRH characterized as iRBD. Physician1 identified one negative case that was classified iRBD by Physician2 and NRH. Additionally, NRH was abnormal in one of the two records with no REM sleep. Discussion NRH may assist in iRBD risk assessment, given it agreed with at least one physician in 86% of the cases and the between-physician iRBD agreement was only fair. NRH also characterized iRBD-risk in patients with insufficient REM sleep for RSWA assessment.
Determination of the Velocity of Sound in a Gas; Application to Analysis of Mixtures of Helium, Oxygen and Nitrogen
Dublin, William B., Boothby, Walter M., Williams, Marvin M. D.

Mayo Clinic

Science | October 7, 2021 | Volume: 90 | Issue: 2339 | Pages: 399-400

10.1126/science.90.2339.399-b Get It

P076 Sleep Staging Agreement Between Polysomnography and Sleep Profiler in Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A45-A46

10.1093/sleepadvances/zpab014.120 Get It

Abstract Purpose Evaluate the sleep staging agreement between polysomnography (PSG) and Sleep Profiler (SP) in patients with suspected isolated REM-sleep-behavior-disorder. Methods Twenty-six patients with reported dream-enactment-behavior (Site1=16, Site2=10; 27% women; age 64±13 years) underwent a diagnostic PSG with simultaneously recorded SP. A registered sleep-technologist at each site performed PSG-staging, while SP was auto-staged and technically reviewed/edited. Across technicians, the initial staging was blinded. Site1 then performed unblinded restaging of PSG=N3(N2) vs. SP=N2(N3) epochs, while Site2 conducted a blinded, carefully-targeted restaging of N3. Statistics included Cohen’s kappa and Chi-square analyses. Results Agreement between SP and Site1 vs. Site2 were significantly different for Wake (kappa:Site1=0.816;Site2=0.650;combined=0.736), stage N1 (kappa:Site1=0.149;Site2=0.228;combined=0.188), stage N2 (kappa:Site1=0.632;Site2=0.718;combined=0.659), stage N3 (kappa:Site1=0.715;Site2=0.368;combined=0.525) and REM (kappa:Site1=0.827;Site2=0.719;combined=0.766)(all P<0.001). After restaging of N3, the kappa values improved at Site1 (unblinded:N2=0.659/N3=0.883) and Site2 (blinded:N2=0.775/N3=0.736)(combined:N2=0.735/N3=0.851). The proportion of PSG-epochs restaged from N3 to N2 was 17% at Sites1 and 38% at Site2 (P<0.001), while Site1 had fewer remaining PSG=N3 vs. SP=N2 conflicts (5.6% vs. 20.8%, P<0.001). Compared to Site2, Site1 had a superior: REM kappa due to fewer SP=N2 disagreements (8.5% vs. 16.8%, P<0.001), and Wake kappa resulting from fewer SP=N1 (6.6 vs. 15.6%, P<0.001) and SP=N2 conflicts (5.9 vs. 12.0%, P<0.001). Conversely, the Site1 N1 kappa was inferior due to greater SP=wake disagreement (41.6% vs. 19.8%, P<0.001). Discussion N3 was excessively stage by both PSG technicians before restaging. At Site1, Wake, N3, and REM had almost-perfect-agreement with SP, while N2 had substantial-agreement. At Site2 and across-site, substantial-agreement was observed for Wake, N2, N3, and REM.
Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients
Park, Sookhyeon , Guo, Kexin , Heilman, Raymond L. , Poggio, Emilio D. , Kurian, Sunil M. , Kleiboeker, Steve, Weems, Juston C. , Holman, John , Zhao, Lihui , Brietigam, S., Rebello, Christabel , Friedewald, John J. , Friedewald, John J , Kurian, Sunil , Taber, David J. , Marsh, Christopher L. , Kleiboeker, Steve , Sinha, Rohita , Abecassis, Michael M.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 7, 2021 | Volume: 16 | Issue: 10 | Pages: 1539-1551

10.2215/cjn.05530421 | PMID 34620649 Get It

Background and objectives Subclinical acute rejection is associated with poor outcomes in kidney transplant recipients. As an alternative to surveillance biopsies, noninvasive screening has been established with a blood gene expression profile. Donor-derived cellfree DNA (cfDNA) has been used to detect rejection in patients with allograft dysfunction but not tested extensively in stable patients. We hypothesized that we could complement noninvasive diagnostic performance for subclinical rejection by combining a donor-derived cfDNA and a gene expression profile assay. Design, setting, participants, & measurements We performed a post hoc analysis of simultaneous blood gene expression profile and donor-derived cfDNA assays in 428 samples paired with surveillance biopsies from 208 subjects enrolled in an observational clinical trial (Clinical Trials in Organ Transplantation-08). Assay results were analyzed as binary variables, and then, their continuous scores were combined using logistic regression. The performance of each assay alone and in combination was compared. Results For diagnosing subclinical rejection, the gene expression profile demonstrated a negative predictive value of 82%, a positive predictive value of 47%, a balanced accuracy of 64%, and an area under the receiver operating curve of 0.75. The donor-derived cfDNA assay showed similar negative predictive value (84%), positive predictive value (56%), balanced accuracy (68%), and area under the receiver operating curve (0.72). When both assays were negative, negative predictive value increased to 88%. When both assays were positive, positive predictive value increased to 81%. Combining assays using multivariable logistic regression, area under the receiver operating curve was 0.81, significantly higher than the gene expression profile ( P <0.001) or donor-derived cfDNA alone ( P =0.006). Notably, when cases were separated on the basis of rejection type, the gene expression profile was significantly better at detecting cellular rejection (area under the receiver operating curve, 0.80 versus 0.62; P =0.001), whereas the donor-derived cfDNA was significantly better at detecting antibody-mediated rejection (area under the receiver operating curve, 0.84 versus 0.71; P =0.003). Conclusions A combination of blood-based biomarkers can improve detection and provide less invasive monitoring for subclinical rejection. In this study, the gene expression profile detected more cellular rejection, whereas donor-derived cfDNA detected more antibody-mediated rejection.
Radiology Implementation Considerations for Artificial Intelligence (AI) Applied to COVID-19, From the AJR Special Series on AI Applications
Mei, Xueyan , Bernheim, Adam , Chung, Michael , Steinberger, Sharon , Kalpathy–Cramer, Jayashree , Little, Brent P. , Li, Matthew , Chang, Ken

Mayo Clinic

American Journal of Roentgenology | October 7, 2021 | Volume: 219 | Issue: 1 | Pages: 15-23

10.2214/ajr.21.26717 | PMID 34612681 Get It